

# RESEARCH REPORT



## CLINICAL LABORATORY MOLECULAR DIAGNOSTICS FOR INFECTIOUS DISEASE MARKETS.

Strategies and Trends. Forecasts by Application (Transplant, Respiratory, etc.)  
by Country. With Market Analysis & Executive Guides.

2023 to 2027





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1 Market Guides .....17

    1.1 Situation Analysis ..... 18

    1.2 Market Shares of Leading Companies – Table and Chart ..... 20

2 Introduction and Market Definition .....22

    2.1 Market Definition ..... 23

        2.1.1 Market Size ..... 23

        2.1.2 Currency ..... 23

        2.1.3 Years ..... 23

    2.2 Methodology ..... 25

        2.2.1 Methodology ..... 25

        2.2.2 Sources ..... 25

        2.2.3 Authors ..... 25

    2.3 Perspective: Healthcare and the IVD Industry ..... 27

        2.3.1 Global Healthcare Spending ..... 27

        2.3.2 Spending on Diagnostics ..... 28

        2.3.3 Important Role of Insurance for Diagnostics ..... 30

3 The Infectious Diseases – Guide to the Pathogens.....31

    3.1 Infectious Disease Pathogens – The Big Picture ..... 32

        3.1.1 Viruses ..... 33

        3.1.2 Bacteria ..... 34

        3.1.3 Fungi ..... 36

        3.1.4 Parasites ..... 36

        3.1.5 Prions ..... 36

- 3.1.6 Virulence ..... 37
- 3.1.7 Transmission..... 37
- 3.2 The Coronavirus..... 38
  - 3.2.1 Severe acute respiratory syndrome (SARS) ..... 40
  - 3.2.2 Middle East respiratory syndrome (MERS) ..... 42
  - 3.2.3 COVID-19. The SARS CoV 2 Virus..... 43
    - 3.2.3.1 Signs and symptoms ..... 44
    - 3.2.3.2 Transmission ..... 45
    - 3.2.3.3 Diagnosis ..... 46
    - 3.2.3.4 Prevention ..... 48
    - 3.2.3.5 Management..... 49
    - 3.2.3.6 Prognosis..... 50
- 3.4 HIV - Human Immunodeficiency Virus (AIDS) ..... 51
  - 3.4.1 Virology ..... 51
    - 3.4.1.1 Classification ..... 51
    - 3.4.1.2 Structure and genome..... 52
    - 3.4.1.3 Tropism..... 54
    - 3.4.1.4 Replication cycle..... 56
    - 3.4.1.5 Genetic variability ..... 62
  - 3.4.2 Diagnosis ..... 64
  - 3.4.3 Testing..... 65
    - 3.4.3.1 Antibody tests ..... 65
    - 3.4.3.2 Point of Care Tests (POCT) ..... 68
    - 3.4.3.3 Antigen Tests ..... 70
    - 3.4.3.4 Nucleic acid-based tests (NAT) ..... 71
    - 3.4.3.5 Other tests used in HIV treatment..... 72

- 3.5 HBV – Hepatitis B..... 74
  - 3.5.1 Virology ..... 75
    - 3.5.1.1 Genome ..... 76
    - 3.5.1.2 Pathogenesis..... 77
    - 3.5.1.3 Hepatitis B virus replication ..... 77
    - 3.5.1.4 Serotypes and genotypes..... 78
  - 3.5.2 Mechanisms..... 78
  - 3.5.3 Diagnosis ..... 79
  - 3.5.4 Market Opportunity Analysis ..... 80
- 3.6 HCV – Hepatitis C..... 82
  - 3.6.1 Taxonomy..... 83
    - 3.6.1.1 Structure ..... 83
    - 3.6.1.2 Genome ..... 84
  - 3.6.2 Molecular biology ..... 85
  - 3.6.3 Replication..... 86
  - 3.6.4 Genotypes ..... 88
    - 3.6.4.1 Clinical importance..... 88
  - 3.6.5 Market Opportunity Analysis ..... 89
- 3.7 HPV - Human papillomavirus..... 90
  - 3.7.1 Virology ..... 92
    - 3.7.1.1 E6/E7 proteins..... 92
    - 3.7.1.2 Role in cancer..... 92
    - 3.7.1.3 E2 research..... 93
    - 3.7.1.4 Latency period ..... 94
    - 3.7.1.5 Clearance ..... 94
  - 3.7.2 Diagnosis ..... 95

3.7.2.1	Cervical testing .....	95
3.7.2.2	Oral testing .....	97
3.7.2.3	Testing men .....	97
3.7.2.4	Other testing .....	98
3.7.3	Market Opportunity Analysis .....	99
3.8	Influenza.....	105
3.8.1	Virology .....	106
3.8.1.1	Types of virus .....	106
3.8.1.2	Influenzavirus A .....	106
3.8.1.3	Influenzavirus B.....	107
3.8.1.4	Influenzavirus C .....	107
3.8.1.5	Structure, properties, and subtype nomenclature .....	108
3.8.1.6	Replication .....	109
3.8.2	Testing.....	111
3.8.2.1	Advantages/Disadvantages of Molecular Assays.....	113
3.8.3	Market Opportunity Analysis .....	114
3.9	CTGC - Chlamydia/Gonorhea .....	123
3.9.1	Gonorrhea .....	123
3.9.1.1	Diagnosis .....	124
3.9.1.2	Screening .....	124
3.9.2	Chlamydia .....	124
3.9.2.1	Diagnosis .....	125
3.9.2.2	Screening .....	126
3.9.3	Testing.....	127
3.9.3.1	Nucleic acid amplification tests (NAATs).....	127
3.9.3.2	Performance of NAAT Tests.....	135

3.9.4	Market Opportunity Analysis .....	136
3.10	Tuberculosis.....	139
3.10.1	Mycobacteria.....	140
3.10.2	Diagnosis .....	141
3.10.2.1	Active tuberculosis .....	141
3.10.2.2	Latent tuberculosis.....	142
3.10.3	Epidemiology .....	142
3.10.4	Molecular Diagnostic Tests .....	144
3.10.5	Market Opportunity Analysis .....	145
3.11	MRSA - Methicillin-resistant Staphylococcus aureus .....	147
3.11.1	Diagnosis .....	147
3.11.2	FDA Approved Molecular Tests .....	148
3.11.3	Market Opportunity Analysis .....	149
3.12	VRE - Vancomycin-resistant Enterococcus .....	151
3.12.1	FDA Approved MDx Tests for VRE.....	152
3.12.2	Market Opportunity Analysis .....	153
3.13	VRE - Vancomycin-resistant Enterococcus.....	153
3.13.1	FDA Approved MDx Tests for VRE.....	154
3.13.2	Market Opportunity Analysis .....	155
4	Industry Overview.....	156
4.1	Players in a Dynamic Market.....	157
4.1.1	Academic Research Lab .....	158
4.1.2	Diagnostic Test Developer.....	158
4.1.3	Instrumentation Supplier .....	159
4.1.4	Chemical/Reagent Supplier.....	159
4.1.5	Pathology Supplier .....	159



4.1.6	Independent Clinical Laboratory .....	160
4.1.7	Public National/regional Laboratory .....	160
4.1.8	Hospital Laboratory .....	161
4.1.9	Physicians Office Lab (POLs) .....	161
4.1.10	Audit Body .....	162
4.1.11	Certification Body.....	162
4.2	The Clinical Laboratory Market Segments .....	164
4.2.1	Traditional Market Segmentation.....	164
4.2.2	Laboratory Focus and Segmentation.....	165
4.2.3	Segmenting the Syndromic Testing Market.....	167
4.3	Industry Structure.....	168
4.3.1	Hospital Testing Share .....	168
4.3.2	Economies of Scale.....	168
4.3.3	Hospital vs. Central Lab .....	169
4.3.4	Physician Office Lab's.....	170
4.3.5	Physician's and POCT .....	170
5	Market Trends .....	172
5.1	Factors Driving Growth .....	173
5.1.1	New Genotypes Creating New Markets .....	174
5.1.2	Aging Population a Boon for All Diagnostics .....	174
5.1.3	Developing World Driving ID Dx Growth.....	175
5.1.4	Point of Care – Why Centralization is Losing Steam .....	175
5.1.5	Self Testing.....	176
5.1.6	The Need for Speed .....	176
5.1.7	The COVID Pandemic.....	176
5.2	Factors Limiting Growth .....	177

5.2.1	Lower Costs.....	177
5.2.2	Infectious Disease is Declining.....	179
5.2.3	Wellness Hurts.....	179
5.2.4	Economic Growth improves Living Standards .....	179
5.3	Instrumentation, Automation and Diagnostic Trends .....	180
5.3.1	Traditional Automation and Centralization.....	180
5.3.2	The New Automation, Decentralization and Point Of Care .....	180
5.3.3	Instruments Key to Market Share .....	182
5.3.4	Bioinformatics Plays a Role .....	182
5.3.5	PCR Takes Command.....	183
5.3.6	Next Generation Sequencing Fuels a Revolution.....	184
5.3.7	NGS Impact on Pricing.....	185
5.3.8	Whole Genome Sequencing, A Brave New World .....	185
5.3.9	Companion Diagnostics Blurs Diagnosis and Treatment .....	186
6	Clinical Laboratory MDx Infectious Disease Recent Developments.....	188
6.1	Recent Developments – Importance and How to Use This Section .....	189
6.1.1	Importance of These Developments .....	189
6.1.2	How to Use This Section.....	189
6.2	Spindiag Seeks Investors for Rapid PCR System.....	189
6.3	Sorrento Therapeutics Nabs Contract for Dx Platform.....	190
6.4	Kepera Planning Menu of Infectious Disease Tests .....	191
6.5	Oxford Nanopore and BioMérieux to Develop IDDX.....	195
6.6	SD Biosensor Eyes Global Expansion.....	195
6.7	Selux Dx Next Gen Phenotyping Gets FDA Clearance.....	200
6.8	Takara Developing High-Throughput Multiplex Panels .....	201
6.9	BioGX Debuts New Point-of-Care Molecular Testing System .....	204

6.10	Nanopath MDx Platform Providing 15-Minute Results.....	209
6.11	ProtonDx Commercializing Rapid MDx Instrument.....	212
6.12	Siemens Healthineers to Develop Next-Gen, High-Throughput MDx Platform.....	214
6.13	Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays.....	217
6.14	Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS.....	218
6.15	Accelerate Diagnostics Anticipates Growth.....	222
6.16	Growth of Decentralized Testing Expected to Continue.....	225
6.17	Lumos Diagnostics Expanding Test Portfolio.....	233
6.18	Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens.....	237
6.19	CareDx, IDbyDNA Develop Infectious Disease Dx for Transplant Patients.....	241
6.20	Accelerated Development of CRISPR as a Diagnostic Platform.....	241
6.21	Lab-on-a-Chip Infection Test Threatens Clinical Laboratory Role.....	246
7	Key Companies and Competitive Analysis.....	249
7.1	Abbott Laboratories.....	250
7.2	Beckman Coulter Diagnostics.....	251
7.3	Becton, Dickinson and Company.....	252
7.4	bioMérieux Diagnostics.....	254
7.5	Bio-Rad Laboratories, Inc.....	256
7.6	Cepheid (Danaher).....	258
7.7	Hologic.....	260
7.8	Ortho Clinical Diagnostics.....	262
7.9	Perkin Elmer.....	263
7.10	Qiagen.....	265
7.11	Roche Molecular Diagnostics.....	267
7.12	Siemens Healthineers.....	269
7.13	Thermo Fisher Scientific Inc.....	270

8	The Global Market for Clinical Laboratory MDx Infectious Disease .....	272
8.1	Global Market Overview by Country .....	273
8.1.1	Table – Global Market by Country.....	273
8.1.2	Chart - Global Market by Country.....	274
8.2	Global Market by Application - Overview.....	275
8.2.1	Table – Global Market by Application .....	275
8.2.2	Chart – Global Market by Application – Base/Final Year Comparison .....	276
8.2.3	Chart – Global Market by Application – Base Year .....	277
8.2.4	Chart – Global Market by Application – End Year .....	278
8.2.5	Chart – Global Market by Application – Share by Year.....	279
8.2.6	Chart – Global Market by Application – Segments Growth.....	280
9	Global Clinical Laboratory MDx Infectious Disease Markets – By Application .....	281
9.1	Respiratory.....	282
9.1.1	Table Respiratory – by Country .....	282
9.1.2	Chart - Respiratory Growth.....	283
9.2	Blood Borne Virus.....	284
9.2.1	Table Blood Borne Virus – by Country .....	284
9.2.2	Chart - Blood Borne Virus Growth .....	285
9.3	Transplant .....	286
9.3.1	Table Transplant – by Country.....	286
9.3.2	Chart - Transplant Growth .....	287
9.4	Hospital Acquired Infections .....	288
9.4.1	Table Hospital Acquired Infections – by Country.....	288
9.4.2	Chart - Hospital Acquired Infections Growth.....	289
9.5	Reproductive Health .....	290
9.5.1	Table Reproductive Health – by Country.....	290

9.5.2 Chart – Reproductive Health Growth..... 291

9.6 C19 Singleplex..... 292

9.6.1 Table C19 Singleplex – by Country ..... 292

9.6.2 Chart – C19 Singleplex Growth ..... 293

9.7 Other ..... 294

9.7.1 Table Other – by Country ..... 294

9.7.2 Chart - Other Growth..... 295

10 Appendices.....296

10.1 United States Medicare System: Laboratory Fees Schedule ..... 297

10.2 The Most Used IVD Assays..... 382

10.3 The Highest Grossing Assays ..... 387

Table of Tables

Table 1 Market Share of Leading Companies ..... 20

Table 2 Viral Pathogens and Families ..... 33

Table 3 Characteristics of Coronavirus Pandemic Infections ..... 43

Table 4 COVID-19 Symptoms..... 45

Table 5 Classification of HIV Species..... 52

Table 6 HBV Tests - CMS Codes & Prices..... 82

Table 7 HCV Tests - CMS Codes & Prices ..... 89

Table 8 HPV Clearance Rates ..... 95

Table 9 HPV Tests - CMS Codes & Prices..... 100

Table 10 HPV Tests, Technology, Types ..... 101

Table 11 Types of Influenza Tests ..... 111

Table 12 Influenza Tests - CMS Codes & Prices..... 114

Table 13 FDA Cleared Molecular Assays for Influenza .....	116
Table 14 FDA Cleared NAAT CTGC Tests .....	128
Table 15 CTGC NAAT Target Sequences and Possible False Reactions .....	133
Table 16 Influenza Tests - CMS Codes & Prices.....	137
Table 17 FDA Approved MDx Tests for Tuberculosis.....	144
Table 18 Tuberculosis Tests - CMS Codes & Prices.....	145
Table 19 FDA Approved Tests for MRSA .....	148
Table 20 MRSA Tests - CMS Codes & Prices .....	150
Table 21 FDA Approved Tests for VRE .....	152
Table 22 VRE Tests - CMS Codes & Prices .....	153
Table 23 FDA Approved Tests for VRE .....	154
Table 24 VRE Tests - CMS Codes & Prices .....	155
Table 25 Market Players by Type .....	158
Table 26 Clinical Laboratory Departments and Segments .....	164
Table 27 Laboratory Management Focus – Different Approaches .....	165
Table 28 Key Segmentation Variables Going Forward.....	166
Table 29 Possible Market Segments of Syndromic Multiplex Market .....	167
Table 30 Five Factors Driving Growth .....	173
Table 31 Four Factors Limiting Growth .....	177
Table 32 Seven Key Diagnostic Laboratory Technology Trends .....	180
Table 33 - Global Market by Region .....	273
Table 34 Global Market by Application.....	275
Table 35 Respiratory by Country.....	282
Table 36 Blood Borne Virus by Country .....	284
Table 37 Transplant by Country .....	286
Table 38 Hospital Acquired Infections by Country.....	288

Table 39 Reproductive Health by Country ..... 290

Table 40 C19 Singleplex by Country..... 292

Table 41 Other by Country..... 294

Table 42 Clinical Lab Fee Schedule ..... 297

Table 43 The Most Common Assays..... 382

Table 44 Largest Revenue Assays..... 387

Table of Figures

Figure 1 Market Share of Leading Companies Chart..... 21

Figure 2 Global Health Care Spending..... 28

Figure 3 The Lab Test Pie ..... 29

Figure 4 Structure of a Typical Virus..... 34

Figure 5 Mycobacterium Tuberculosis ..... 35

FIGURE 6 STRUCTURE OF CORONAVIRUSES ..... 39

Figure 7 HIV Virion ..... 53

Figure 8 Diagram of the HIV Replication Cycle ..... 57

Figure 9 The Structure of the HBV Virus..... 76

Figure 10 Hepatitis B Replication ..... 77

Figure 11 Structure of the HCV Virus..... 84

Figure 12 HCV Replication Cycle ..... 87

Figure 13 Structure of the Influenza Virion ..... 108

Figure 14 Influenza Replication..... 109

Figure 15 Scanning Electronmicrograph of Tuberculosis..... 140

Figure 16 The Road to Diagnostics ..... 157

Figure 17 Percentage of World Population Over 65..... 175

Figure 18 Chart Infectious Disease Decline ..... 178

Figure 19 Centralized vs. Decentralized Laboratory Service ..... 181

Figure 20 A Highly Multiplexed Syndromic Testing Unit..... 181

Figure 21 The Real Cost to Sequence the Human Genome..... 184

Figure 22 The Codevelopment Process ..... 186

Figure 23 Global Market Share Chart ..... 274

Figure 24 Global Market by Application - Base vs. Final ..... 276

Figure 25 Global Market by Application Base Year..... 277

Figure 26 Global Market by Application End Year ..... 278

Figure 27 Application Share by Year..... 279

Figure 28 Application Segments Growth..... 280

Figure 29 Respiratory Growth..... 283

Figure 30 Blood Borne Virus Diagnostics Growth..... 285

Figure 31 Transplant Growth ..... 287

Figure 32 Hospital Acquired Infections Growth..... 289

Figure 33 Reproductive Health Growth ..... 291

Figure 34 C19 Singleplex Growth..... 293

Figure 35 Other Growth..... 295